167 related articles for article (PubMed ID: 21069102)
1. Acceptability and tolerability of levetiracetam oral solution for the treatment of partial-onset seizures: the SOLUCIÓN study.
Matías-Guíu J; Molins A; Mauri JA; Villar E
Methods Find Exp Clin Pharmacol; 2010 Sep; 32(7):507-16. PubMed ID: 21069102
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.
Piña-Garza JE; Nordli DR; Rating D; Yang H; Schiemann-Delgado J; Duncan B;
Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423
[TBL] [Abstract][Full Text] [Related]
4. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.
Baulac M; Brodie MJ; Elger CE; Krakow K; Stockis A; Meyvisch P; Falter U
Epilepsia; 2007 Mar; 48(3):589-92. PubMed ID: 17326794
[TBL] [Abstract][Full Text] [Related]
5. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
6. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of levetiracetam: a review of three pivotal clinical trials.
Privitera M
Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of levetiracetam.
Arroyo S; Crawford P
Epileptic Disord; 2003 May; 5 Suppl 1():S57-63. PubMed ID: 12915343
[TBL] [Abstract][Full Text] [Related]
9. Intravenous levetiracetam in children with seizures: a prospective safety study.
Ng YT; Hastriter EV; Cardenas JF; Khoury EM; Chapman KE
J Child Neurol; 2010 May; 25(5):551-5. PubMed ID: 20413804
[TBL] [Abstract][Full Text] [Related]
10. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
11. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets.
Coupez R; Straetemans R; Sehgal G; Stockis A; Lu ZS
J Clin Pharmacol; 2003 Dec; 43(12):1370-6. PubMed ID: 14615473
[TBL] [Abstract][Full Text] [Related]
12. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks.
Piña-Garza JE; Schiemann-Delgado J; Yang H; Duncan B; Hadac J; Hunter SJ
Clin Ther; 2010 Oct; 32(11):1935-50. PubMed ID: 21095488
[TBL] [Abstract][Full Text] [Related]
14. Intravenous levetiracetam in children with epilepsy.
Goraya JS; Khurana DS; Valencia I; Melvin JJ; Cruz M; Legido A; Kothare SV
Pediatr Neurol; 2008 Mar; 38(3):177-80. PubMed ID: 18279751
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
Li S; Cao J; Xiao N; Cai F
J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
[TBL] [Abstract][Full Text] [Related]
16. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
17. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial.
Levisohn PM; Mintz M; Hunter SJ; Yang H; Jones J;
Epilepsia; 2009 Nov; 50(11):2377-89. PubMed ID: 19702752
[TBL] [Abstract][Full Text] [Related]
18. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
Xiao Z; Li JM; Wang XF; Xiao F; Xi ZQ; Lv Y; Sun HB
Eur Neurol; 2009; 61(4):233-9. PubMed ID: 19176965
[TBL] [Abstract][Full Text] [Related]
20. Role of levetiracetam in the treatment of epilepsy.
Brodie MJ; French JA
Epileptic Disord; 2003 May; 5 Suppl 1():S65-72. PubMed ID: 12915344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
